Tempest Therapeutics (TPST) Other Non Operating Income (2014 - 2026)
Tempest Therapeutics (TPST) posted Other Non Operating Income of $56000.0 for Q4 2025, down 34.88% sequentially from $86000.0 in Q3 2025, and up 609.09% YoY from $7897.4 in Q4 2024.
Tempest Therapeutics (TPST) Other Non Operating Income (2014 - 2026) Analysis & Trends
Tempest Therapeutics has reported Other Non Operating Income for 12 years, with the latest figure at $56000.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 609.09% year-over-year to $56000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $521000.0 (down 54.1% YoY) and the FY2025 annual result came in at $520000.0, down 54.23% from the prior year.
- Other Non Operating Income retreated to $56000.0 in Q4 2025 per TPST's latest filing, from $86000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.3 million in Q4 2022 and troughed at -$341000.0 in Q4 2023.
- A 5-year average of $282764.7 and a median of $179000.0 in 2023 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 9533.33% in 2023, down 114.7% in 2023.
- Over 5 years, Other Non Operating Income stood at $174000.0 in 2021, then soared by 1233.33% to $2.3 million in 2022, then slumped by 114.7% to -$341000.0 in 2023, then soared by 96.77% to -$11000.0 in 2024, then soared by 609.09% to $56000.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $56000.0, $86000.0, and $142000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Dec 31, 2025 | 56,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 237,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 438,000.00 |
| Dec 31, 2023 | -341,000.00 |
| Sep 30, 2023 | 179,000.00 |
| Jun 30, 2023 | 244,000.00 |
| Mar 31, 2023 | 289,000.00 |
| Dec 31, 2022 | 2.32 Mn |
| Sep 30, 2022 | 213,000.00 |
| Jun 30, 2022 | 70,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Mar 31, 2021 | 174,000.00 |
| Dec 31, 2020 | 498,000.00 |
| Sep 30, 2020 | -310,000.00 |